Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Background We analysed the effect of ivabradine on outcomes in heart failure (HF) patients on recommended background therapies with heart rates ≥75 bpm and <75 bpm in the SHIFT trial. A cut-off value of ≥75 bpm was chosen by the EMEA for approval for the use of ivabradine in chronic heart failure.Methods The SHIFT population was divided by baseline heart rate ≥75 or <75 bpm. The effect of ivabradine was analysed for primary composite endpoint (cardiovascular death or HF hospitalization) and other endpoints.Results In the ≥75 bpm group, ivabradine reduced primary endpoint (HR 0.76, 95 % CI 0.68-0.85, P < 0.0001), all-cause mortality (HR 0.83, 95 % CI, 0.72-0.96, P = 0.0109), cardiovascular mortality (HR 0.83, 95 % CI, (0.71-0.97, P = 0.0166), HF death (HR 0.61, 95 % CI, 0.46-0.81, P < 0.0006), and HF hospitalization (HR 0.70, 95 % CI, 0.61-0.80, P < 0.0001). Risk reduction depended on heart rate after 28 days, with the best protection for heart rates <60 bpm or reductions >10 bpm. None of the endpoints was significantly reduced in the <75 bpm group, though there were trends for risk reductions in HF death and hospitalization for heart rate <60 bpm and reductions >10 bpm. Ivabradine was tolerated similarly in both groups.Conclusion The effect of ivabradine on outcomes is greater in patients with heart rate ≥75 bpm with heart rates achieved <60 bpm or heart rate reductions >10 bpm predicting best risk reduction. Our findings emphasize the importance of identification of high-risk HF patients by high heart rates and their treatment with heart rate-lowering drugs such as ivabradine.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Studies have shown that most titration of β-blockade occurs early in the course of treatment, with most of the heart rate reduction occurring at < 50% of target dose.”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [62]
Citations
Cites
Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study
Swedberg, K., Komajda, M., Böhm, M., Borer, J. S., Ford, I., Dubost-Brama, A., Lerebours, G., & Tavazzi, L. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61198-1 · Cited by 2,563
Self-citationCleland, J. (2003) · European Heart Journal · doi:10.1016/s0195-668x(02)00823-0 · Cited by 1,549
Böhm, M., Swedberg, K., Komajda, M., Borer, J. S., Ford, I., Dubost-Brama, A., Lerebours, G., & Tavazzi, L. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61259-7 · Cited by 1,099
Self-citationDiaz, A., Bourassa, M. G., Guertin, M.-C., & Tardif, J.-C. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi190 · Cited by 790
Kolloch, R., Legler, U. F., Champion, A., Cooper-DeHoff, R. M., Handberg, E., Zhou, Q., & Pepine, C. J. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehn123 · Cited by 330
Conway, M. A., Allis, J., Ouwerkerk, R., Niioka, T., Rajagopalan, B., & Radda, G. K. (1991) · The Lancet · doi:10.1016/0140-6736(91)91838-l · Cited by 322
Tardif, J.-C., O'Meara, E., Komajda, M., Böhm, M., Borer, J. S., Ford, I., Tavazzi, L., & Swedberg, K. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr311 · Cited by 300
Self-citationMulder, P., Barbier, S., Chagraoui, A., Richard, V., Henry, J. P., Lallemand, F., Renet, S., Lerebours, G., Mahlberg-Gaudin, F., & Thuillez, C. (2004) · Circulation · doi:10.1161/01.cir.0000118464.48959.1c · Cited by 294
Current-dependent Block of Rabbit Sino-Atrial Node If Channels by Ivabradine
Bucchi, A., Baruscotti, M., & DiFrancesco, D. (2002) · The Journal of General Physiology · doi:10.1085/jgp.20028593 · Cited by 289
Custodis, F., Baumhäkel, M., Schlimmer, N., List, F., Gensch, C., Böhm, M., & Laufs, U. (2008) · Circulation · doi:10.1161/circulationaha.107.746537 · Cited by 263
Self-citation
Cited by
Items 101–200 of 250
Böhm, M., Abdin, A., Slawik, J., Mahfoud, F., BORER, J. S., Ford, I., Swedberg, K. B., Tavazzi, L., Batailler, C., & Komajda, M. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.2870 · Cited by 15
“00 Ischaemic cause of heart failure 2215 (68) 2203 (67) 1359 (66) 1363 (65) Myocardial infarction 1829 (56) 1837 (56) 1124 (55) 1138 (54) Hypertension 2162 (67) 2152 (66) 1333 (65) 1349 (64) Diabetes 973 (30) 1006 (31) 638 (31) 665 (32) Previous stroke 228 (7) 295 (9) 141 (7) 189 (9) Atrial fibrillation and/or flutter…”
Self-citationHeart failure in elderly: progress in clinical evaluation and therapeutic approach.
Iacoviello, M., & Antoncecchi, V. (2013) · PubMed Central · doi:10.3969/j.issn.1671-5411.2013.02.010 · Cited by 14
Role of Ivabradine in the Treatment of Patients With Cardiovascular Disease
Weeda, E. R., Nguyen, E., & White, C. M. (2016) · Annals of Pharmacotherapy · doi:10.1177/1060028016631571 · Cited by 14
“05) than in those with baseline heart rates <75 bpm.(37) The cohort with heart rates ≥75 bpm derived greater decreases in the primary end point when heart rate was lowered to <60 bpm (HR = 0.”
ResultBöhm, M. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.689 · Cited by 13
Self-citationBenefit–risk review of different drug classes used in chronic heart failure
Andries, G., Yandrapalli, S., & Aronow, W. S. (2018) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1512580 · Cited by 13
Alpha-crystallin: an ATP-independent complete molecular chaperone toward sorbitol dehydrogenase
Marini, I., Moschini, R., CORSO, A. D., & Mura, U. (2005) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-005-4474-z · Cited by 13
Tereshchenko, S. N., Жиров, И. В., Uskach, T. M., Saidova, M. A., Sp, G., Михайловна, Г. Е., Николаевна, Н. С., Narusov, O. Y., Safiullina, A. A., Tereshchenko, A. S., et al. (2020) · Eurasian heart journal · doi:10.38109/2225-1685-2020-3-6-76 · Cited by 13
Sympathetic Activation in Chronic Heart Failure: Potential Benefits of Interventional Therapies
Lachowska, K., Gruchała, M., Narkiewicz, K., & Hering, D. (2016) · Current Hypertension Reports · doi:10.1007/s11906-016-0660-7 · Cited by 15
Chamarthi, B., Vinik, A. I., Ezrokhi, M., & Cincotta, A. H. (2019) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.101 · Cited by 12
Heart Rate As a Biomarker in Heart Failure: Role of Heart Rate Lowering Agents
Shaaya, G., Al-Khazaali, A., & Arora, R. R. (2015) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000000336 · Cited by 12
“The findings emphasize the importance of identification of high-risk HF patients with high HR and their treatment with HR-lowering drugs such as ivabradine.(31) Analysis of 24-hour Holter recordings was a prespecified substudy of SHIFT for exploring the heart rhythm safety of ivabradine and to determine the effects of…”
BackgroundChen, C., Zhong, W., Zheng, H., Zhao, W., Wang, Y., & Shen, B. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1518036 · Cited by 13
Ivabradine: In Adults with Chronic Heart Failure with Reduced Left Ventricular Ejection Fraction
Perry, C. M. (2012) · American Journal of Cardiovascular Drugs · doi:10.1007/bf03262475 · Cited by 11
“In addition to subanalyses included in the main report of the SHIFT study, several substudies of the SHIFT study have been conducted (and reported separately) and are also reviewed.([34-39]) The antianginal and anti-ischemic efficacy of ivabradine has been demonstrated in several randomized controlled trials in patien…”
Ivabradine in patients with heart failure: a systematic literature review
Khan, Z., Brière, J., Olewińska, E., Khrouf, F., & Nikodem, M. (2023) · Journal of Market Access & Health Policy · doi:10.1080/20016689.2023.2262073 · Cited by 10
“A SHIFT analysis revealed that patients with a baseline heart rate of 75 bpm or higher may benefit more from ivabradine treatment, which was not associated with a significant reduction in CV and all-cause deaths [11].”
BackgroundMethodInfluentialHidalgo, F. J. (2017) · International Journal of Clinical Cardiology · doi:10.23937/2378-2951/1410093 · Cited by 10
“A directly proportional relationship between HR reduction and prognostic improvement has been observed [3,4].”
BackgroundResultAbdin, A., Anker, S. D., Cowie, M., Filippatos, G. S., Ponikowski, P. P., Tavazzi, L., Schöpe, J., Wagenpfeil, S., Komajda, M., & Böhm, M. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.3023 · Cited by 11
“23,26 RHR is not only a marker for the increased incidence of adverse outcomes, but may also be a modifiable risk factor in patients with HF, and strategies to reduce heart rate improve outcome.”
BackgroundSelf-citationTsai, M., Lin, S.-I., Kao, Y.-C., Lin, H., Lin, M., Peng, J., Wang, C., Wu, V. C., Cheng, C., Lee, Y., et al. (2023) · Medicina · doi:10.3390/medicina59020348 · Cited by 11
“Ivabradine can be used to further reduce the heart rates of patients with HFrEF with sinus rhythm heart rates over 70 bpm, and help such patients achieve more favorable clinical outcomes, including a lower risk of mortality, especially when a patient’s heart rate can be reduced by ≥15 bpm [12,29].”
BackgroundIvabradine therapy to unmask heart rate-independent effects of β-blockers on pulse wave reflections
Fischer‐Rasokat, U., Honold, J., Lochmann, D., Liebetrau, C., Leick, J., Hamm, C. W., Fichtlscherer, S., Möllmann, H., & Spyridopoulos, I. (2014) · Clinical Research in Cardiology · doi:10.1007/s00392-014-0679-1 · Cited by 9
Chen, A. B., Elia, N., Dunaiceva, J., Rudiger, A., Walder, B., & Pinto, B. B. (2020) · British Journal of Anaesthesia · doi:10.1016/j.bja.2020.01.027 · Cited by 11
Abdin, A., Komajda, M., BORER, J. S., Ford, I., Tavazzi, L., Batailler, C., Swedberg, K. B., Rosano, G. M. C., Mahfoud, F., Böhm, M., et al. (2023) · ESC Heart Failure · doi:10.1002/ehf2.14455 · Cited by 10
“10,11,14,21 Across all these groups, ivabradine led to a similar risk reduction of outcomes.”
Self-citationElder, D. H. J., Mohan, M., Cochrane, L., Charles, H., & Lang, C. C. (2015) · Cardiovascular Therapeutics · doi:10.1111/1755-5922.12117 · Cited by 9
Effect of Reducing Heart Rate on Outcomes in Patients With Reduced Ejection Fraction
Lan, W.-R., Lin, S.-I., Liao, F., Chang, H., Tsai, C.-T., Wu, Y.-J., Liu, P., Chen, C.-H., & Lee, Y. (2021) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2021.03.050 · Cited by 10
Gomes, J. A. (2020) · Springer eBooks · doi:10.1007/978-3-030-45066-3_22 · Cited by 9
Tereshchenko, S. N., Жиров, И. В., Uskach, T. M., Saidova, M. A., Sp, G., Rimskaya, E. M., Николаевна, Н. С., Narusov, O. Y., Safiullina, A. A., Tereshchenko, A. S., et al. (2024) · Eurasian heart journal · doi:10.38109/2225-1685-2024-2-6-76 · Cited by 9
Current drug therapy for heart failure with reduced ejection fraction
Berliner, D., Hallbaum, M., & Bauersachs, J. K. (2018) · Herz · doi:10.1007/s00059-018-4712-4 · Cited by 8
Heart rate and heart failure: the role of ivabradine therapy
Reil, J., & Böhm, M. (2013) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e32836043af · Cited by 9
“The effect of ivabradine on outcomes was greater in patients with baseline heart rate of at least 75 bpm, with heart rates achieved less than 60 bpm or heart rate reductions greater than 10 bpm predicting best risk reduction ([20]; Fig.”
BackgroundSelf-citationNguyen, E., Weeda, E. R., & White, C. M. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.677 · Cited by 9
Patel, P. A., Ali, N., Roy, A., Pinder, S., Cubbon, R. M., Kearney, M. T., & Witte, K. K. (2018) · Journal of General Internal Medicine · doi:10.1007/s11606-018-4578-4 · Cited by 8
Chin, K. L., Collier, T. J., Pocock, S., Pitt, B., McMurray, J. J. V., van Veldhuisen, D. J., Swedberg, K. B., Vincent, J., Zannad, F. M., & Liew, D. (2019) · Clinical Research in Cardiology · doi:10.1007/s00392-018-1410-4 · Cited by 8
Self-citationГеоргиевна, В. Н., Polyakov, D. S., Fomin, I. V., & Жиркова, М. М. (2019) · Kardiologiia · doi:10.18087/cardio.2622 · Cited by 8
Unidades de insuficiência cardíaca: estado da arte na abordagem da insuficiência cardíaca
Timóteo, A. T., Pereira‐da‐Silva, T., Moreira, R. I., Gonçalves, A., Soares, R. M., & Ferreira, F. (2020) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2020.02.007 · Cited by 11
Paterek, A., Sochanowicz, B., Oknińska, M., Śmigielski, W., Kruszewski, M. K., Mackiewicz, U., Ma̧czewski, M., & Leszek, P. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111250 · Cited by 8
Adams, K. F., Giblin, E. M., Pearce, N., & Patterson, J. H. (2017) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1934 · Cited by 7
Clinical Implications of Ivabradine in the Contemporary Era
Imamura, T. (2024) · Medicina · doi:10.3390/medicina60020303 · Cited by 7
“…to achieve a discernible prognostic bene fi t among patients entering the trial with a baseline heart rate equal to or exceeding 75 beats per minute [10]. diminish cardiac output, characterized by a reduction in the summation of all stroke volumes per minute, potentially culminating in a…”
BackgroundInfluentialNúñez, L., Crespo-Leiro, M. G., Marrón-Liñares, G. M., Suárez-Fuentetaja, N., Barge‐Caballero, E., Paniagua-Martín, M. J., Marzoa‐Rivas, R., Grille-Cancela, Z., Muñiz, J., Vázquez‐Rodríguez, J. M., et al. (2013) · Cardiology Journal · doi:10.5603/cj.a2016.0050 · Cited by 7
Ivabradine in Congestive Heart Failure: Patient Selection and Perspectives
Sattar, Y., Samani, E. N., Zafrullah, F., Latchana, S., & Patel, N. B. (2019) · Cureus · doi:10.7759/cureus.4448 · Cited by 7
2025 Clinical practice guidelines for Dilated cardiomyopathy
Chesnikova, A. I., Sitnikova, M. Y., Ageev, F. T., Arutyunov, G. P., Баутин, А. Е., Begrambekova, Y. L., Belenkov, Y. N., Vasyuk, Y. A., Георгиевна, В. Н., Galyavich, A. S., et al. (2026) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2026-6672 · Cited by 8
‘Inappropriate’ Sinus Tachycardia: Does the 100 Beats Per Min cut-off matter?
Hottigoudar, R. U., & Gopinathannair, R. (2013) · Future Cardiology · doi:10.2217/fca.13.5 · Cited by 6
Musiałek, P. (2013) · Kardiologia Polska · doi:10.5603/kp.2013.0168 · Cited by 6
“Despite this important limitation, SHIfT still demonstrated a mortality benefit [9, 33], part of which is likely to arise from the action of ivabradine in diseased ventricular myocardium.”
BackgroundInfluentialNiewydolność serca — okres okołowypisowy kluczowym elementem postępowania
Lelonek, M. (2018) · Folia Cardiologica · doi:10.5603/fc.2018.0080 · Cited by 6
Sharma, A. D., Wilkoff, B. L., Richards, M., Wold, N. D., Jones, P. W., Perschbacher, D., & Olshansky, B. (2021) · Heart Rhythm · doi:10.1016/j.hrthm.2021.07.068 · Cited by 6
Akute und chronische Herzinsuffizienz im Spiegel der neuen ESC-Leitlinie
Pöss, J., Link, A., & Böhm, M. (2013) · Herz · doi:10.1007/s00059-013-3986-9 · Cited by 6
Self-citationIvabradine for chronic heart failure?
(2012) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.2012.10.0136 · Cited by 6
Role of ivabradine and heart rate lowering in chronic heart failure: guideline update
Chow, S. L., Page, R. L., II, & Depré, C. (2018) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2018.1489235 · Cited by 6
“Among patients with a baseline heart rate ≥75 bpm, patients who achieved at least a 10 bpm decrease in heart rate on ivabradine therapy had the most impactful clinical outcomes [70].”
BackgroundYang, J., Lv, T., Zhou, J., Lin, H., Zhao, B., Lou, H., Liu, H., Zhang, T., Guo, H., & Chi, J. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1149351 · Cited by 5
Effect of Ivabradine on Heart Failure: A 2024 Meta-Analysis
Maharaj, A., Maturasingh, M. B., Khangembam, A., Bidhesi, S., Rai, S., Garness, K. A., Khadoo, N., Tutwala, N., Khan, N., Ramsarran, J. J., et al. (2025) · Cureus · doi:10.7759/cureus.77346 · Cited by 5
“…results showing a greater effect on the HR >75 beats per minute (bpm) group that comprised younger patients with other factors to consider (smokers, lower LVEF, higher New York Heart Association (NYHA) classification, and non-ischemic HF), suggesting that certain age groups may benefit more [22].”
Cada, D. J., Bindler, R. J., & Baker, D. E. (2015) · Hospital Pharmacy · doi:10.1310/hpj5009-806 · Cited by 5
Misconceptions and Facts about Heart Failure with Reduced Ejection Fraction
Krittanawong, C., Rodriguez, M., Lui, M., Misra, A., Tang, W. H. W., Bozkurt, B., & Yancy, C. W. (2023) · The American Journal of Medicine · doi:10.1016/j.amjmed.2023.01.024 · Cited by 6
Ashraf, S., Khalaf, A. K. S., Fatima, L., Hashim, H. T., Irfan, H., Ashfaq, H., Khan, M. A., Zahid, A., Akram, U., & Goyal, A. (2024) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2024.102604 · Cited by 5
Bonet, L. A., Zunzunegui, J. L., Barón‐Esquivias, G., Carrasco, J. I., Gómez‐Doblas, J. J., Colet, J. C., Barrios, V., Subirana, M., & Molina, B. D. (2013) · Revista Española de Cardiología · doi:10.1016/j.recesp.2012.10.022 · Cited by 7
Knosalla, C., Gummert, J. F., Edelmann, F., Störk, S., Ertl, G., Falk, V., & Prien, P. (2018) · Zeitschrift für Herz- Thorax- und Gefäßchirurgie · doi:10.1007/s00398-018-0240-z · Cited by 5
“DieNVL folgt hier hingegen der Zulassung der European Medicines Agency (EMA), die auf einer Meta- [6] und einer Post-hocAnalyse [7] der Zulassungsstudie SHIFT beruht.”
BackgroundThe role of heart rate and ivabradine in acute heart failure
Sciatti, E., Vizzardi, E., Bonadei, I., Dallapellegrina, L., & Carubelli, V. (2019) · Monaldi Archives for Chest Disease · doi:10.4081/monaldi.2019.1091 · Cited by 8
Kawasaki, S., Sakai, Y., Harasawa, S., Inatsu, A., Kubota, Y., Hirama, A., Kashiwagi, T., & Iwabu, M. (2024) · Therapeutic Apheresis and Dialysis · doi:10.1111/1744-9987.14107 · Cited by 5
Howlett, J. G. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1936 · Cited by 5
Clinical utility of ivabradine in cardiovascular disease management: current status
Rosano, G. M. C., Vitale, C., Spoletini, I., & Volterrani, M. (2014) · Research Reports in Clinical Cardiology · doi:10.2147/rrcc.s46468 · Cited by 4
“In a subsequent post hoc analysis of the SHIFT requested by the EMA, 25 in patients with heart rate $ 75 bpm, ivabradine was shown to reduce all-cause mortality (17% risk reduction), therefore suggesting that the higher the baseline heart rate the greater the effect of the drug.”
Ivabradine: the start of a SHIFT in heart failure treatment
Cowie, M. (2013) · Interventional Cardiology · doi:10.2217/ica.12.78 · Cited by 4
Old and New Drugs for Treatment of Advanced Heart Failure
Buttà, C., Roberto, M., Tuttolomondo, A., Petrantoni, R., Miceli, G., Zappia, L., & Pinto, A. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612826666191226165402 · Cited by 4
Long-term outcome of carvedilol therapy in Japanese patients with nonischemic heart failure
Nagara, K., Suzuki, A., Shiga, T., & Hagiwara, N. (2020) · Heart and Vessels · doi:10.1007/s00380-020-01560-w · Cited by 4
Chronotropic Assessment in Patients with Constrictive Pericarditis
Imamura, T., Narang, N., Besser, S. A., & Kinugawa, K. (2021) · International Heart Journal · doi:10.1536/ihj.20-751 · Cited by 4
“Right atrial pressure, mmHg 11 (9, 12) 10 (8, 12) 11 (9, 12) 12 (10, 14) 0.”
Slowing Heart Rate Protects Against Pathological Cardiac Hypertrophy
Sebastian, S. T., Weinstein, L. S., Ludwig, A., Munroe, P. B., & Tinker, A. (2022) · Function · doi:10.1093/function/zqac055 · Cited by 4
Clark, A. L. (2013) · Heart · doi:10.1136/heartjnl-2013-304761 · Cited by 4
BORER, J. S., Kansal, A. R., Dorman, E., Krotneva, S., Zheng, Y., Patel, H., Tavazzi, L., Michel Komajda, N., Ford, I., Böhm, M., et al. (2016) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2016.22.9.1064 · Cited by 4
Self-citationHohneck, A. L., Fries, P., Stroeder, J., Schneider, G. K., Schirmer, S. H., Reil, J., Böhm, M., Laufs, U., & Custodis, F. (2021) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2021.100757 · Cited by 4
“Resting heart rate (RHR) impacts outcome in patients with various cardiovascular diseases [1,2] and affects cardiovascular function and physiology [3].”
BackgroundSelf-citationOomman, A., & Bansal, M. (2018) · Indian Heart Journal · doi:10.1016/j.ihj.2018.03.009 · Cited by 5
“The best protection was observed for those with HR <60 bpm or >10 bpm reduction in HR at 28 days after initiation of the treatment.(18) Even among patients with baseline HR <75 bpm, in whom no overall benefit was seen with ivabradine, there were trends for reductions in HF mortality and HF hospitalizations for HR <60…”
BackgroundProgress in the Presence of Failure: Updates in Chronic Systolic Heart Failure Management
Murphy, K. M., & Rosenthal, J. (2017) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-017-0552-4 · Cited by 5
“Subsequent subgroup analysis showed that the benefits of ivabradine plus BB were independent of baseline BB dose and were due to the magnitude of heart rate reduction [36].”
BackgroundPagel, P. S., Hang, D., Freed, J. K., & Crystal, G. J. (2025) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2025.03.029 · Cited by 3
Nationale Versorgungsleitlinie (NVL) Chronische KHK: Was ist neu, was ist besonders wichtig?
Werdan, K. (2016) · CME · doi:10.1007/s11298-016-5747-6 · Cited by 4
“Nach retrospektiver Auswertung der SHIFTStudie [51, 60] kam die Europäische Arzneimittelagentur (EMA) zu dem Schluss, Ivabradin bei Patienten mit Sinusrhythmus von 75/min oder mehr zuzulassen, da eine signifikante Senkung der kardiovaskulären Letalität um 17%, der herzinsuffizienzbedingten Letalität um 39% und der her…”
BackgroundIvabradine for Treatment of Heart Failure with Preserved Ejection Fraction
Бабушкина, Г. В., & Shaikhlislamova, G. I. (2020) · Kardiologiia · doi:10.18087/cardio.2020.10.n1324 · Cited by 3
Chronische Herzinsuffizienz: Aktuelle Leitlinienempfehlungen und neue Erkenntnisse
Ewen, S., Mahfoud, F., & Böhm, M. (2015) · Der Internist · doi:10.1007/s00108-015-3703-2 · Cited by 3
Self-citationEfficacy of Doppler echocardiography-guided ivabradine therapy
Izumida, T., Imamura, T., & Kinugawa, K. (2022) · Heart and Vessels · doi:10.1007/s00380-022-02127-7 · Cited by 3
Tanaka, H., Yamauchi, Y., Imanishi, J., Hatani, Y., Hayashi, T., & Hirata, K. (2020) · Journal of Cardiology · doi:10.1016/j.jjcc.2020.12.012 · Cited by 3
Tereshchenko, S. N., V., Z. I., & Романова, Н. В. (2016) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2016-8-80-85 · Cited by 4
Medical Treatment of Heart Failure with Reduced Ejection Fraction – Prognostic Indication
Rosano, G. M. C. (2017) · International Cardiovascular Forum Journal · doi:10.17987/icfj.v10i0.422 · Cited by 2
“The SHIFT study has shown that the mortality benefit of ivabradine is related to its heart rate reducing effect and that is greatest in patients achieving a heart rate <60 bpm.[21] The combined analysis of the SHIFT study in patients with HFrEF and of the Beautiful study in patients with ischaemic left ventricular dys…”
ResultImamura, T., Onoda, H., Uchida, K., & Kinugawa, K. (2021) · International Heart Journal · doi:10.1536/ihj.21-387 · Cited by 2
Kutyifa, V., Burch, A. E., Aßmus, B., Bonderman, D., Bianco, N. R., Russo, A. M., & Erath, J. W. (2024) · Heart Rhythm O2 · doi:10.1016/j.hroo.2024.04.008 · Cited by 2
Advances in understanding and managing pediatric heart failure and transplant
Xu, W., & Richmond, M. E. (2024) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000001393 · Cited by 2
Principles of Outpatient Care of Patients With Heart Failure
Drapkina, O. M., & Chesnikova, A. I. (2024) · Kardiologiia · doi:10.18087/cardio.2024.11.n2797 · Cited by 2
Li, X., Yang, Y., Zhu, X., Xia, H., & Tan, Z. W. (2025) · European journal of medical research · doi:10.1186/s40001-025-02574-8 · Cited by 2
“The SHIFT study concluded that ivabradine or β-blockers had the best effect on outcomes in HF patients with HR reduction > 10 bpm or who achieved HR 60 bpm [41].”
Vagal Nerve Stimulation for the Treatment of Heart Failure
Radcliffe, E. J., & Trafford, A. W. (2017) · Springer eBooks · doi:10.1007/978-3-319-28612-9_7 · Cited by 2
Novelties in the treatment of heart failure
Souček, F., & Novák, J. (2017) · Vnitřní lékařství · doi:10.36290/vnl.2017.053 · Cited by 2
Update on Heart Failure, Heart Transplant, Congenital Heart Disease, and Clinical Cardiology
Almenar, L., Zunzunegui, J. L., Barón‐Esquivias, G., Carrasco, J. I., Gómez‐Doblas, J. J., Colet, J. C., Barrios, V., Subirana, M., & Molina, B. D. (2013) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2012.10.018 · Cited by 3
“The baseline heart rate of the candidate for treatment with ivabradine seems to be a crucial factor: in one of the SHIFT substudies published in 2011, treatment with ivabradine showed improvement in important ‘‘hard’’ endpoints such as all-cause mortality and cardiovascular mortality in the cohort of patients with a b…”
BackgroundMelander, S. D., & Miller, S. (2016) · Nursing Clinics of North America · doi:10.1016/j.cnur.2015.11.004 · Cited by 2
“Additionally, Ivabrandine is a hyperpolarization-activated cyclic nucleotide-gated channel blocker that was evaluated in the SHIFT (Systolic Heart failure trial with the If inhibitor Ivabrandine) trial and is shown to reduce the risk of hospitalization and cardiovascular death in patients with chronic NYHA class II to…”
MethodManagement of Patients with Heart Failure: Focus on New Pharmaceutical and Device Options
Briasoulis, Α., Inampudi, C., Hatzis, G., & Asleh, R. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190523083747 · Cited by 2
The role of resistance to inhibitors of cholinesterase 8b in the control of heart rate
Sebastian, S. T., Nobles, M., Tsisanova, E., Ludwig, A., Munroe, P. B., & Tinker, A. (2021) · Physiological Genomics · doi:10.1152/physiolgenomics.00157.2020 · Cited by 2
Nationale Versorgungsleitlinie (NVL) Chronische KHK: Was ist neu, was ist besonders wichtig?
Werdan, K. (2016) · Herz · doi:10.1007/s00059-016-4474-9 · Cited by 3
“Nach retrospektiver Auswertung der SHIFT-Studie [51, 60] kam die Europäische Arzneimittelagentur (EMA) zu dem Schluss, Ivabradin bei Patienten mit Sinusrhythmus von 75/min oder mehr zuzulassen, da eine signifikante Senkung der kardiovaskulären Letalität um 17%, der herzinsuffizienzbedingten Letalität um 39% und der he…”
Inoue, T., Matsunaga, K., Kobayashi, W., & Minamino, T. (2023) · Clinical Case Reports · doi:10.1002/ccr3.6890 · Cited by 2
Zhou, J., Xu, Y., Zheng, Z., Zhang, S., Yang, J., Zhang, Y., Tang, B., Han, H., Zhang, Q., Liu, F., et al. (2024) · ESC Heart Failure · doi:10.1002/ehf2.14581 · Cited by 2
“14 Our fi ndings of signi fi cant improvements in LVEF and NYHA class were also consistent with the Chinese subgroup analysis from SHIFT.”
ResultIvabradine and atrial fibrillation: what should we tell our patients?
Cowie, M. (2014) · Heart · doi:10.1136/heartjnl-2014-306287 · Cited by 2
Editorial: Reappraisal of increasing heart rate for cardiac performance
Akaishi, M. (2013) · Journal of Cardiology Cases · doi:10.1016/j.jccase.2013.11.003 · Cited by 2
The beneficial effects of ivabradine against myocardial damage induced by isoproterenol in rats
Polat, S., Altuntas, M., Günata, M., Polat, A., Tanrıverdi, L. H., Yıldız, A., Durhan, M., Vardı, N., Çiğremiş, Y., Acet, H., et al. (2023) · Medicine Science | International Medical Journal · doi:10.5455/medscience.2023.03.042 · Cited by 1
Inomata, T., Fukuda, T., Yamashita, N., Niibe, K., Demiya, S., Matsuda, H., & Igarashi, A. (2024) · International Heart Journal · doi:10.1536/ihj.24-194 · Cited by 1
Imai, H., & Shimada, J. (2025) · Cureus · doi:10.7759/cureus.80232 · Cited by 1
“In addition, ivabradine, a chronic heart failure drug, reduced cardiovascular-related deaths (cardiovascular death) and hospitalization for worsening heart failure by decreasing heart rate [8,9].”
Mullasari, A., Abdullakutty, J., Suryavanshi, S., Gadkari, M. A., Aggrawal, R. K., Sable, A., & Sawant, P. (2026) · Cureus · doi:10.7759/cureus.108875 · Cited by 1
“However, those with a baseline RHR 75 bpm did not show a statistically significant reduction in outcomes, as the drug had less effect on lower-risk conditions [22].”
HEART RATE-LOWERING THERAPY IN THE TREATMENT OF CHRONIC HEART FAILURE
Шалаев, С. В., Silicic, L. V., & Abaturova, O. V. (2015) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2015-11-1-79-84 · Cited by 3
Újdonságok a krónikus szívelégtelenség gyógyszeres terápiájában
Nyolczas, N. (2016) · Orvosi Hetilap · doi:10.1556/650.2016.30579 · Cited by 1
Пономарева, А. И., Геннадьевна, К. О., Линчак, Р. М., & Ivanchura, G. S. (2016) · Systemic Hypertension · doi:10.26442/sg29135 · Cited by 1
Ivabradine for heart failure: regulatory differences in Europe and United States
Marciniak, T. A., Hall, T. S., Atar, D., Agewall, S., & Serebruany, V. L. (2019) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvz006 · Cited by 1
Clark, A. L. (2013) · Seminars in Cardiovascular Medicine · doi:10.2478/semcard-2013-0007 · Cited by 1
“The benefit seen was largely a reduction in hospitalisation for heart failure, but a post hoc analysis suggested that there may be a survival benefit for patients with a resting heart rate ≥ 75/min [22].”
BackgroundBejarano, J. M. L., Domingo, M., González, A. M., Verdú-Rotellar, J. M., Rodríguez, Á. C., & Robleda, L. E. (2014) · FMC - Formación Médica Continuada en Atención Primaria · doi:10.1016/s1134-2072(14)70875-8 · Cited by 3
Chang, H., Huang, H., Wang, C.-Y., Lo, H., Chen, H.-J., Feng, A., Fong, M., Chen, C.-N., Chang, H.-C., Chiang, K.-F., et al. (2022) · PubMed · doi:10.6515/acs.202207_38(4).20211228b · Cited by 3
Hernández, J. E. E. (2023) · Revista Virtual de la Sociedad Paraguaya de Medicina Interna · doi:10.18004/rvspmi/2312-3893/2023.10.02.99 · Cited by 2
Metadata
- Authors
- Böhm, M., Borer, J., Ford, I., Gonzalez-Juanatey, J. R., Komajda, M., Lopez-Sendon, J., Reil, J.-C., Swedberg, K., & Tavazzi, L.
- Affiliations
- Universitätsklinikum des Saarlandes (DE)
- SUNY Downstate Health Sciences University (US)
- University of Glasgow (GB)
- Hospital Universitario La Paz (ES)
- University of Gothenburg (SE)
- Maria Cecilia Hospital (IT)
- Corresponding author
- Böhm, Michael
- Reil, Jan-Christian
- ORCID
- Venue
- Clinical Research in Cardiology
- Published
- 2012-05-11
- Volume
- 102
- Issue
- 1
- Pages
- 11-22
- ISSN
- 1861-0684 (ISSN-L)
- 1861-0692
- OpenAlex
- W2045247934
- Cited by
- 248
- References
- 18
- Citations by year
- 2026: 4 · 2025: 7 · 2024: 15 · 2023: 15 · 2022: 13 · 2021: 16 · 2020: 19 · 2019: 19 · 2018: 18 · 2017: 16 · 2016: 34 · 2015: 15 · 2014: 19 · 2013: 27 · 2012: 10
- FWCI
- 14.61
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- other-oa
- www.springer.com/tdm (tdm)
- Locations
- Clinical Research in Cardiology (publishedVersion)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- RUNA. Repositorio Institucional del Sergas (Servicio Gallego de Salud (SERGAS)) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Rate Variability and Autonomic Control
- Keywords
- ivabradine, chronic heart failure, baseline heart rate, SHIFT trial, cardiovascular mortality, heart failure hospitalization, heart rate reduction, all-cause mortality
- MeSH terms
- Ivabradine, Aged, Anti-Arrhythmia Agents, Benzazepines, Chronic Disease, Double-Blind Method, Female, Heart Failure, Heart Rate, Hospitalization, Humans, Male, Middle Aged, Risk Factors, Time Factors, Proportional Hazards Models, Treatment Outcome, Disease Progression, Risk Assessment, Patient Selection, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.